Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

[Adjusting or not adjusting isoniazid dosage?].

R Parrot, C Boval, J Grosset

Revue Francaise Des Maladies Respiratoires

|January 1, 1983

Summary

Adjusting Isoniazid dosage for acetylator status in triple therapy did not significantly improve treatment outcomes or reduce toxicity in tuberculosis patients. Standard dosing proved equally effective and safe.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Vulvar lichen sclerosus in children misdiagnosed as sexual abuse].

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2015

Same author

[Fatal hemorrhage in postpartum by rupture of a splenic artery aneurysm].

Gynecologie, obstetrique & fertilite·2013

Same author

[Postmortem CT-angiography: feasibility of US-guided vascular access].

Journal de radiologie·2011

Same author

Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection.

Antimicrobial agents and chemotherapy·2010

Same author

Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease.

The European respiratory journal·2005

Same author

Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.

Antimicrobial agents and chemotherapy·2005

Area of Science:

Pharmacology
Infectious Diseases
Clinical Medicine

Background:

Tuberculosis treatment commonly uses triple therapy, including Isoniazid.
Isoniazid metabolism varies based on acetylator status, influencing drug efficacy and toxicity.
Previous research suggested dose adjustment might optimize Isoniazid therapy.

Purpose of the Study:

To compare the efficacy and toxicity of standard Isoniazid dosing versus acetylator status-adjusted dosing in triple therapy for tuberculosis.
To evaluate the clinical benefit of personalized Isoniazid dosage based on patient acetylation phenotype.

Main Methods:

A comparative study involving 299 patients (standard dose) and 448 patients (adjusted dose) treated with Rifampicin, Ethambutol, and Isoniazid.
Serum Isoniazid concentrations were measured at 3, 6, and 12 hours post-administration.
Efficacy and toxicity were assessed between the two treatment groups.

Main Results:

No statistically significant differences in treatment efficacy were observed between the standard and adjusted Isoniazid dosage groups.
Similarly, no significant differences in toxicity profiles were noted between the two patient cohorts.
Serum Isoniazid concentrations did not reveal a clear advantage for adjusted dosing in this study population.

Conclusions:

Adjusting Isoniazid dosage based on acetylator status did not provide statistically significant clinical benefits in this patient cohort.
Standard Isoniazid dosing in combination therapy appears to be as effective and safe as adjusted dosing.
Further research may be needed to identify specific patient subgroups that could benefit from personalized Isoniazid dosing.

Related Experiment Videos